Thermo Fisher Scientific Stock Earnings Reports

Thermo Fisher delivered a strong start to 2026 with Q1 revenue of $11.01B (up 6%), adjusted operating income of $2.4B (up 6%), and adjusted EPS of $5.44 (up 6%). Management raised full-year guidance: revenue now $47.3B–$48.1B (6%–8% reported growth; assumes 3%–4% organic) and adjusted EPS $24.64–$25.12 (8%–10% growth). Key growth drivers were bioproduction, clinical research (strong revenue and authorizations), and research & safety channels; Academic & Government and Diagnostics experienced softer demand, particularly in the U.S. and China. The company completed the Clario acquisition (digital endpoint data solutions), which contributed ~$30M to Q1 revenue and was included in the guidance raise (+$900M to 2026 revenue at the midpoint). Management emphasized ongoing high-impact innovation (new instruments and lab systems), strategic collaborations (NVIDIA, SHL Medical), active cost/productivity management via the PPI Business System, and deploying AI across the business. Operational execution offset tariff and FX headwinds; adjusted operating margin expanded modestly and productivity funded investments. Balance sheet actions: $3B share repurchases in Q1, 10% dividend increase, Clario acquisition financed (approx. $9B), quarter-end leverage ~3.8x gross debt/EBITDA. Risks/uncertainties cited: potential modest inflationary pressure (placeholder in guide), tariffs/FX, and macro/geopolitical complexity (Middle East). Management scheduled an Analyst Day for May 20, 2026.